Skip to main content

Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy.

Publication ,  Journal Article
Leung, VWS; Ng, CKC; Lam, S-K; Wong, P-T; Ng, K-Y; Tam, C-H; Lee, T-C; Chow, K-C; Chow, Y-K; Tam, VCW; Lee, SWY; Lim, FMY; Wu, JQ; Cai, J
Published in: J Pers Med
November 24, 2023

Given the high death rate caused by high-risk prostate cancer (PCa) (>40%) and the reliability issues associated with traditional prognostic markers, the purpose of this study is to investigate planning computed tomography (pCT)-based radiomics for the long-term prognostication of high-risk localized PCa patients who received whole pelvic radiotherapy (WPRT). This is a retrospective study with methods based on best practice procedures for radiomics research. Sixty-four patients were selected and randomly assigned to training (n = 45) and testing (n = 19) cohorts for radiomics model development with five major steps: pCT image acquisition using a Philips Big Bore CT simulator; multiple manual segmentations of clinical target volume for the prostate (CTVprostate) on the pCT images; feature extraction from the CTVprostate using PyRadiomics; feature selection for overfitting avoidance; and model development with three-fold cross-validation. The radiomics model and signature performances were evaluated based on the area under the receiver operating characteristic curve (AUC) as well as accuracy, sensitivity and specificity. This study's results show that our pCT-based radiomics model was able to predict the six-year progression-free survival of the high-risk localized PCa patients who received the WPRT with highly consistent performances (mean AUC: 0.76 (training) and 0.71 (testing)). These are comparable to findings of other similar studies including those using magnetic resonance imaging (MRI)-based radiomics. The accuracy, sensitivity and specificity of our radiomics signature that consisted of two texture features were 0.778, 0.833 and 0.556 (training) and 0.842, 0.867 and 0.750 (testing), respectively. Since CT is more readily available than MRI and is the standard-of-care modality for PCa WPRT planning, pCT-based radiomics could be used as a routine non-invasive approach to the prognostic prediction of WPRT treatment outcomes in high-risk localized PCa.

Duke Scholars

Published In

J Pers Med

DOI

ISSN

2075-4426

Publication Date

November 24, 2023

Volume

13

Issue

12

Location

Switzerland

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3206 Medical biotechnology
  • 3205 Medical biochemistry and metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Leung, V. W. S., Ng, C. K. C., Lam, S.-K., Wong, P.-T., Ng, K.-Y., Tam, C.-H., … Cai, J. (2023). Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy. J Pers Med, 13(12). https://doi.org/10.3390/jpm13121643
Leung, Vincent W. S., Curtise K. C. Ng, Sai-Kit Lam, Po-Tsz Wong, Ka-Yan Ng, Cheuk-Hong Tam, Tsz-Ching Lee, et al. “Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy.J Pers Med 13, no. 12 (November 24, 2023). https://doi.org/10.3390/jpm13121643.
Leung, Vincent W. S., et al. “Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy.J Pers Med, vol. 13, no. 12, Nov. 2023. Pubmed, doi:10.3390/jpm13121643.
Leung VWS, Ng CKC, Lam S-K, Wong P-T, Ng K-Y, Tam C-H, Lee T-C, Chow K-C, Chow Y-K, Tam VCW, Lee SWY, Lim FMY, Wu JQ, Cai J. Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy. J Pers Med. 2023 Nov 24;13(12).

Published In

J Pers Med

DOI

ISSN

2075-4426

Publication Date

November 24, 2023

Volume

13

Issue

12

Location

Switzerland

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3206 Medical biotechnology
  • 3205 Medical biochemistry and metabolomics